Diana Spiegelberg Selected Research

Neoplasms (Cancer)

1/2020	The Novel Anti-cMet Antibody seeMet 12 Potentiates Sorafenib Therapy and Radiotherapy in a Colorectal Cancer Model.
1/2020	Overcoming Limitations of Cisplatin Therapy by Additional Treatment With the HSP90 Inhibitor Onalespib.
1/2020	The radiosensitizer Onalespib increases complete remission in 177Lu-DOTATATE-treated mice bearing neuroendocrine tumor xenografts.
1/2020	The HSP90 inhibitor Onalespib exerts synergistic anti-cancer effects when combined with radiotherapy: an in vitro and in vivo approach.
1/2019	The Stapled Peptide PM2 Stabilizes p53 Levels and Radiosensitizes Wild-Type p53 Cancer Cells.
1/2018	The MDM2/MDMX-p53 Antagonist PM2 Radiosensitizes Wild-Type p53 Tumors.
5/2016	Molecular imaging of EGFR and CD44v6 for prediction and response monitoring of HSP90 inhibition in an in vivo squamous cell carcinoma model.
2/2016	Evaluation of a novel type of imaging probe based on a recombinant bivalent mini-antibody construct for detection of CD44v6-expressing squamous cell carcinoma.
1/2016	A real-time in vitro assay as a potential predictor of in vivo tumor imaging properties.
11/2015	The novel HSP90 inhibitor AT13387 potentiates radiation effects in squamous cell carcinoma and adenocarcinoma cells.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Diana Spiegelberg Research Topics

Disease

12	Neoplasms (Cancer) 01/2020 - 10/2011
5	Squamous Cell Carcinoma (Epidermoid Carcinoma) 05/2016 - 02/2014
2	Colorectal Neoplasms (Colorectal Cancer) 01/2020 - 01/2012
2	Neuroendocrine Tumors (Neuroendocrine Tumor) 01/2020 - 12/2019
2	Squamous Cell Carcinoma of Head and Neck 01/2017 - 10/2011
1	Gastrointestinal Neoplasms (Gastrointestinal Cancer) 01/2020
1	Head and Neck Neoplasms (Head and Neck Cancer) 01/2020
1	Adenocarcinoma 11/2015
1	Carcinoma (Carcinomatosis) 09/2014
1	Colonic Neoplasms (Colon Cancer) 01/2014

Drug/Important Bio-Agent (IBA)

6	(2,4- dihydroxy- 5- isopropylphenyl)- (5- (4- methylpiperazin- 1- ylmethyl)- 1,3- dihydroisoindol- 2- yl)methanoneIBA 01/2020 - 11/2015
3	Proteins (Proteins, Gene)FDA Link 01/2020 - 02/2014
3	ErbB Receptors (EGF Receptor)IBA 09/2014 - 10/2011
2	Heat-Shock Proteins (Heat-Shock Protein)IBA 01/2020 - 11/2015
2	Somatostatin Receptors (Somatostatin Receptor)IBA 01/2020 - 12/2019
2	Therapeutic UsesIBA 01/2020 - 01/2019
2	Peptides (Polypeptides)IBA 01/2019 - 01/2018
2	Pharmaceutical PreparationsIBA 01/2017 - 11/2015
2	Immunoglobulin FragmentsIBA 02/2016 - 01/2016
2	Radioisotopes (Radionuclides)IBA 11/2015 - 10/2011
1	antineoplaston A10 (A 10)IBA 01/2020
1	A-factor (Streptomyces)IBA 01/2020
1	lutetium Lu 177 dotatateIBA 01/2020
1	Sorafenib (BAY 43-9006)FDA Link 01/2020
1	Cisplatin (Platino)FDA LinkGeneric 01/2020
1	Tyrosine Kinase InhibitorsIBA 01/2020
1	AntibodiesIBA 01/2017
1	Surface Antigens (Surface Antigen)IBA 05/2016
1	Biomarkers (Surrogate Marker)IBA 05/2016
1	AntigensIBA 05/2016
1	CD44v6 antigenIBA 02/2016
1	Glucose (Dextrose)FDA LinkGeneric 02/2016
1	Fluorodeoxyglucose F18 (Fludeoxyglucose F 18)FDA Link 02/2016
1	Immunoglobulin Fab FragmentsIBA 03/2014
1	IsotopesIBA 03/2014
1	Fluorescein-5-isothiocyanate (FITC)IBA 02/2014
1	Membrane Proteins (Integral Membrane Proteins)IBA 01/2014
1	Protein Isoforms (Isoforms)IBA 01/2014
1	Growth Factor ReceptorsIBA 10/2011
1	Epidermal Growth Factor (EGF)IBA 10/2011

Therapy/Procedure

6	Therapeutics 01/2020 - 11/2015
4	Radiotherapy 01/2020 - 01/2018
1	Radioimmunotherapy 05/2016